Aptose Biosciences INC 8-K filings

Aptose Biosciences Inc. reported the immediate resignation of Carol Ashe from its Board of Directors, effective June 16, 2025, with no stated disagreements regarding company operations or policies.

Aptose Biosciences Inc. announced a short-term, non-interest bearing cash advance from its CEO, Dr. William G. Rice, to cover near-term obligations and continue clinical development of tuspetinib, while also disclosing a board resignation and potential insolvency without further funding.

Aptose Biosciences announced promising safety and efficacy data from its TUSCANY Phase 1/2 clinical trial of tuspetinib triplet therapy in newly diagnosed AML patients, presented at the 2025 European Hematology Association Congress.

Aptose Biosciences Inc. announced that shareholders approved all proposals at its Annual and Special Meeting, including director re-elections, executive compensation, a stock incentive plan amendment, and a potential reverse stock split, though the meeting was adjourned to finalize the appointment of a new auditor.

Aptose Biosciences reports positive safety and efficacy data, leading to dose escalation in the Phase 1/2 Tuscany trial of tuspetinib-based triple drug therapy for newly diagnosed AML patients.

Aptose Biosciences announces that data from its Phase 1/2 TUSCANY trial of tuspetinib in combination with venetoclax and azacitidine for newly diagnosed AML will be presented at the European Hematology Association Congress in June 2025.

Aptose Biosciences announces positive initial data from its TUSCANY trial of tuspetinib in AML, while also highlighting concerns about its short-term cash runway and ongoing financing efforts.

Aptose Biosciences reports positive early data from its Phase 1/2 TUSCANY trial, showcasing the potential of tuspetinib in combination with venetoclax and azacitidine as a frontline therapy for newly diagnosed AML patients.

Aptose Biosciences announces that KPMG will not stand for re-appointment as the company's independent auditor for the 2025 annual audit.

Aptose Biosciences reports that KPMG will not seek re-appointment as their independent auditor for the 2025 annual audit, and the company is initiating a search for a new auditor.

Aptose Biosciences Inc. received a delisting notice from Nasdaq due to non-compliance with the minimum stockholder equity requirement, effective April 2, 2025.

Aptose Biosciences Inc. will be delisted from the Nasdaq Stock Market effective April 2, 2025, due to non-compliance with the Exchange's equity requirements.

Aptose Biosciences announced its year-end 2024 financial results and provided a corporate update, highlighting the advancement of tuspetinib-based triple drug therapy for acute myeloid leukemia (AML).

Aptose Biosciences Inc. converts $1.5 million of debt into equity with Hanmi Pharmaceutical and amends investor rights agreement to include board observer rights and registration rights.

Aptose Biosciences announces it has regained compliance with Nasdaq's minimum bid price requirement, but is still working to meet shareholders equity compliance requirements.

Aptose Biosciences is advancing tuspetinib as a key component of a triplet therapy for newly diagnosed Acute Myeloid Leukemia (AML), aiming to improve patient outcomes and overcome limitations of current treatments.

Aptose Biosciences implements a 1-for-30 reverse stock split to commence trading on a split-adjusted basis on February 26, 2025.

Aptose Biosciences receives approval to escalate the dosage in its Phase 1/2 Tuscany trial of tuspetinib-based triple drug therapy for newly diagnosed AML patients after promising early results.

Aptose Biosciences plans a 1-for-30 reverse share split to meet Nasdaq's minimum bid price requirement and broaden investor access.

Aptose Biosciences has entered into a common share purchase agreement for a $25 million committed equity facility and established a new at-the-market (ATM) facility.

Aptose Biosciences has entered into a $25 million committed equity facility agreement and established a new at-the-market (ATM) offering to raise additional capital.

Aptose Biosciences reports encouraging early results from its TUSCANY trial, where a tuspetinib-based triple therapy achieved notable responses in newly diagnosed acute myeloid leukemia (AML) patients.

Aptose Biosciences has established an at-the-market sales facility to potentially sell up to $1 million of its common shares through A.G.P./Alliance Global Partners.

Aptose Biosciences shareholders have approved a reverse stock split and a measure to adjourn the meeting if necessary to secure sufficient votes.

Aptose Biosciences received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement and is seeking shareholder approval for a reverse stock split to regain compliance.

Aptose Biosciences is progressing its Tuspetinib-based triplet therapy for acute myeloid leukemia (AML), having secured funding and partnerships to support clinical trials.

Aptose Biosciences has dosed the first patients in its TUSCANY Phase 1/2 trial, evaluating a triplet therapy of tuspetinib, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia (AML).

Aptose Biosciences has received an extension from Nasdaq to meet listing requirements by March 31, 2025, following a hearing and recent positive developments.

Aptose Biosciences has published preclinical data demonstrating the unique mechanism of action of tuspetinib and its synthetic lethality when combined with venetoclax in treating acute myeloid leukemia (AML).

Aptose Biosciences presented clinical data at the ASH Annual Meeting supporting the use of tuspetinib in combination therapies for acute myeloid leukemia (AML), including a triplet therapy for newly diagnosed patients.